WO2011056721A3 - Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité - Google Patents

Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité Download PDF

Info

Publication number
WO2011056721A3
WO2011056721A3 PCT/US2010/054668 US2010054668W WO2011056721A3 WO 2011056721 A3 WO2011056721 A3 WO 2011056721A3 US 2010054668 W US2010054668 W US 2010054668W WO 2011056721 A3 WO2011056721 A3 WO 2011056721A3
Authority
WO
WIPO (PCT)
Prior art keywords
poxvirus
subunit
immunoconjugates
antibodies against
presenting cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/054668
Other languages
English (en)
Other versions
WO2011056721A2 (fr
Inventor
Alice P. Taylor
Boby Makabi-Panzu
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Molecular Medicine and Immunology
Original Assignee
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed by Center for Molecular Medicine and Immunology filed Critical Center for Molecular Medicine and Immunology
Priority to CA2776563A priority Critical patent/CA2776563A1/fr
Priority to EP10828938.0A priority patent/EP2496256A4/fr
Priority to AU2010315432A priority patent/AU2010315432A1/en
Priority to CN2010800474188A priority patent/CN102573902A/zh
Priority to IN2692DEN2012 priority patent/IN2012DN02692A/en
Publication of WO2011056721A2 publication Critical patent/WO2011056721A2/fr
Publication of WO2011056721A3 publication Critical patent/WO2011056721A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur des procédés et des compositions pour des vaccins à base de sous unité pour induire une immunité contre des infections par un poxvirus, telles que la variole. Des modes de réalisation préférés concernent des immunoconjugués comprenant un ou plusieurs peptides antigéniques de sous-unité attachés à un anticorps ou à un fragment de celui-ci qui cible des cellules de production d'antigènes (APC). Plus préférentiellement, l'anticorps se lie à HLA-DR et le peptide antigénique provient d'un facteur immunomodulateur, tel que la protéine virale de liaison à IL-18 (vIL18BP). Cependant, des mélanges de peptides antigéniques provenant de différentes protéines virales peuvent également être utilisés. Le vaccin est capable d'induire une immunité à l'encontre d'un poxvirus sans risque d'infection disséminée dans des hôtes immunocompromis ou de transmission à des contacts sensibles.
PCT/US2010/054668 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité Ceased WO2011056721A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2776563A CA2776563A1 (fr) 2009-11-05 2010-10-29 Immunoconjugues comprenant des peptides issus de poxvirus et des anticorps diriges contre des cellules presentatrices d'un antigene pour des vaccins contre les poxvirus a base desous-unite
EP10828938.0A EP2496256A4 (fr) 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité
AU2010315432A AU2010315432A1 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
CN2010800474188A CN102573902A (zh) 2009-11-05 2010-10-29 用于基于亚单位的痘病毒疫苗的包含痘病毒衍生肽和针对抗原呈递细胞的抗体的免疫偶联物
IN2692DEN2012 IN2012DN02692A (fr) 2009-11-05 2010-10-29

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US25836909P 2009-11-05 2009-11-05
US61/258,369 2009-11-05
US25872909P 2009-11-06 2009-11-06
US61/258,729 2009-11-06
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,140 2010-04-05
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US12/754,740 2010-04-06
US37805910P 2010-08-30 2010-08-30
US61/378,059 2010-08-30

Publications (2)

Publication Number Publication Date
WO2011056721A2 WO2011056721A2 (fr) 2011-05-12
WO2011056721A3 true WO2011056721A3 (fr) 2011-10-13

Family

ID=43970701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/054668 Ceased WO2011056721A2 (fr) 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité

Country Status (6)

Country Link
EP (1) EP2496256A4 (fr)
CN (1) CN102573902A (fr)
AU (1) AU2010315432A1 (fr)
CA (1) CA2776563A1 (fr)
IN (1) IN2012DN02692A (fr)
WO (1) WO2011056721A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150238632A1 (en) * 2012-09-18 2015-08-27 University Of Washington Through Its Center For Commercialization Compositions and Methods for Delivery of Antigens to Plasmacytoid Dendritic Cells
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
CN109187982B (zh) * 2018-08-02 2021-06-04 浙江康佰裕生物科技有限公司 一种tlr类疫苗佐剂的筛选和鉴定方法
EP3870217A4 (fr) * 2018-10-22 2022-08-31 Icellkealex Therapeutics LLC Virus de la vaccine mutants et leur utilisation
CN111474339A (zh) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 一种利用荧光标记痘病毒颗粒的方法及其应用
KR20230003122A (ko) * 2020-04-27 2023-01-05 제노비에 에이비 바이러스 비-비리온-통합 유래 에피토프에 대한 인간 백혈구 항원 클래스 i 제한 cd8 t-세포 반응을 프라이밍하기 위한 백신 조성물의 생성 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291208B1 (en) * 1995-06-07 2001-09-18 Aventis Pasteur Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
US7612180B2 (en) * 2005-03-03 2009-11-03 Immunomedics, Inc. Humanized L243 antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (fr) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Polypeptide de fusion au vih
WO1996040941A1 (fr) * 1995-06-07 1996-12-19 Connaught Laboratories Limited Anticorps chimeriques pour l'acheminement d'antigenes jusqu'a des cellules selectionnees du systeme immunitaire
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
WO2003093296A2 (fr) * 2002-05-03 2003-11-13 Sequenom, Inc. Muteines de proteines d'ancrage de kinase, leurs peptides, et procedes associes
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
WO2004094613A2 (fr) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Complexe proteinique polyvalent
CA2604032C (fr) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methodes de generation de complexes lies stablement composes d'homodimeres, d'homotetrameres ou de dimeres de dimeres et utilisations associees
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CA2607056C (fr) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Procedes et compositions permettant de produire des ensembles bioactifs de complexite augmentee et utilisations
SG153825A1 (en) * 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
WO2007134037A2 (fr) * 2006-05-15 2007-11-22 Immunomedics, Inc. Procédés et compositions de traitement d'infections par le virus de l'immunodéficience humaine avec des anticorps ou des fragments d'anticorps conjugués
AU2009233925B2 (en) * 2006-12-05 2014-03-13 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291208B1 (en) * 1995-06-07 2001-09-18 Aventis Pasteur Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
US7612180B2 (en) * 2005-03-03 2009-11-03 Immunomedics, Inc. Humanized L243 antibodies
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 8 December 2008 (2008-12-08), "IL-18 binding protein [Variola virus].", XP008157392, Database accession no. 042049 *
KRUMM ET AL.: "Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18 -binding protein.", PROC NATL ACAD SCI USA, vol. 105, no. 52, 2008, pages 20711 - 20715, XP008157395 *
MENG ET AL.: "Variola virus IL-18 binding protein interacts with three human IL-18 residues that are part of a binding site for human IL-18 receptor alpha subunit.", VIROLOGY, vol. 358, no. 1, 2007, pages 211 - 220, XP008157403 *
See also references of EP2496256A4 *
VAN VLIET ET AL.: "Poxvirus proteomics and virus-host protein interactions.", MICROBIOL MOL BIOL REV., vol. 73, no. 4, December 2009 (2009-12-01), pages 730 - 749, XP008157390 *

Also Published As

Publication number Publication date
AU2010315432A1 (en) 2012-04-12
EP2496256A2 (fr) 2012-09-12
CN102573902A (zh) 2012-07-11
WO2011056721A2 (fr) 2011-05-12
EP2496256A4 (fr) 2013-07-17
IN2012DN02692A (fr) 2015-09-04
CA2776563A1 (fr) 2011-05-12

Similar Documents

Publication Publication Date Title
WO2011056721A3 (fr) Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité
WO2020193688A3 (fr) Compositions immunogènes et vaccins comprenant des peptides et des protéines du virus de la peste porcine africaine et leurs utilisations
WO2007095318A3 (fr) antigenes de la grippe, compositions de vaccins et procedes associes
WO2007008918A3 (fr) Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee
WO2012034025A3 (fr) Vaccin à cytomégalovirus humain
WO2007095320A3 (fr) Antigènes du papillomavirus humain, compositions de vaccin et méthodes
WO2009128949A3 (fr) Compositions de proteines du virus de la dengue et methodes d’utilisation associees
EA201492110A1 (ru) Вакцины против впг-2
WO2009026397A3 (fr) Vaccins antigrippaux prophylactiques et thérapeutiques, antigènes, compositions et procédés
WO2007106476A3 (fr) Compositions et procédés pour renforcer l'immunogénicité d'antigènes
WO2009012487A3 (fr) Pseudo-particules virales du virus chimère de la varicelle et du zona
EP3156070A3 (fr) Vaccins du virus de l'herpès vectorisé par le virus de la maladie de newcastle
WO2008124646A3 (fr) Utilisation de protéines amyloïdes en tant qu'échafaudages pour des vaccins
WO2006113214A3 (fr) Vaccin contre des souches pandemiques des virus de la grippe
MX2024004293A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
WO2010149752A3 (fr) Nouvelles compositions
WO2016176624A3 (fr) Pestivirus porcin, vaccins et dosages
WO2010079505A3 (fr) Vaccin combine rougeole-papillome humain
MY170659A (en) Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
WO2006110728A3 (fr) Agregats de tegument immunogenes
WO2008134643A3 (fr) Antigènes de trypanosome, compositions de vaccins et procédés associés
WO2017142843A8 (fr) Nouvel antigène destiné à être utilisé dans un vaccin antipaludique
WO2016116905A9 (fr) Antigènes de cmv et leurs utilisations
EP3971298A3 (fr) Compositions et méthodes permettant d'induire une réponse immunitaire améliorée au moyen des vecteurs de poxvirus

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080047418.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10828938

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010315432

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2692/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2776563

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010315432

Country of ref document: AU

Date of ref document: 20101029

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010828938

Country of ref document: EP